TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT

Summary

The purpose of this study is to test the feasibility and safety of early cessation of tacrolimus following allogeneic hematopoietic cell transplantation (HCT). Post-HCT tacrolimus is given to prevent graft-vs-host-disease (GVHD), but with the use of post-transplant cyclophosphamide (PTCy), the modern approach to GVHD prevention, GVHD rates have reduced markedly.

Timeline

Start

2026-06

Primary completion

2028-02

Completion

2028-02

Drugs

Indications